Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab Combined With Ipilimumab (N01) Plus Albumin-bound Paclitaxel and Gemcitabine (AG) as First-line Therapy for Unresectable Locally Advanced or Metastatic Biliary Tract Malignancies: A Prospective Phase II Clinical Study.

NCT07654530 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT07654530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07654530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab Combined With Ipilimumab (N01) Plus Albumin-bound Paclitaxel and Gemcitabine (AG) as First-line Therapy for Unresectable Locally Advanced or Metastatic Biliary Tract Malignancies: A Prospective Phase II Clinical Study.
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 24, 2026
Completion date
June 30, 2028
Enrollment
107 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancers (btc)